ES2467105T5 - Moxifloxacino compactado - Google Patents

Moxifloxacino compactado Download PDF

Info

Publication number
ES2467105T5
ES2467105T5 ES09765042.8T ES09765042T ES2467105T5 ES 2467105 T5 ES2467105 T5 ES 2467105T5 ES 09765042 T ES09765042 T ES 09765042T ES 2467105 T5 ES2467105 T5 ES 2467105T5
Authority
ES
Spain
Prior art keywords
moxifloxacin
compacted
tablets
film
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09765042.8T
Other languages
English (en)
Other versions
ES2467105T3 (es
Inventor
Dieter Swatschek
Max Werner Scheiwe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2467105(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Application granted granted Critical
Publication of ES2467105T3 publication Critical patent/ES2467105T3/es
Publication of ES2467105T5 publication Critical patent/ES2467105T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
8.000), dióxido de titanio y pigmentos colorantes.
Ejemplos según la invención 4, 4a, 5 y 5a
5 De forma análoga a los ejemplos 1-3 y 1a-3a se prepararon los ejemplos 4-5 y 4a-5a, usándose moxifloxacino en forma de base libre en vez de la sal clorhidrato.
Las cantidades usadas se dan en la tabla 2.
10 Ejemplo comparativo 6
Se fabricó un núcleo de comprimido tal como se describe en el ejemplo 6 del documento EP 1 128 831 B1, mediante granulación en húmedo. Las cantidades usadas se dan en la tabla 3.
15 Comparación de las propiedades físicas
Se comparan las propiedades físicas de los comprimidos resultantes en la tabla 4.
Se muestra que los comprimidos fabricados mediante compactación (en seco) (tanto recubiertos con película como
20 también no recubiertos con película) muestran propiedades ventajosas con respecto a la resistencia a la rotura y la friabilidad. Además, los comprimidos según la invención se pueden barnizar mejor, se producen menos desprendimientos.
Además, se muestra que las formulaciones exentas de lactosa muestran una mejor uniformidad de contenido.
25 En conjunto, puede concluirse que con el procedimiento según la invención puede influirse positivamente en las propiedades físicas de los comprimidos resultantes. Además, el procedimiento según la invención es ventajoso en el aspecto de disminución de coste energético, que no es óptimo en el caso del procedimiento del estado de la técnica, ya que, en primer lugar, se introduce la humedad en forma de solución granulada y, después, debe eliminarse de
30 nuevo con un procedimiento de secado caro.
imagen11
Tabla 2
Ejemplo 4
Ejemplo 5
Núcleo
mg % en peso Mg % en peso
Moxifloxacino (base libre)
400,00 58,93 400,00 58,93
CMC (celulosa microcristalina)
231,80 34,15 230,80 34,00
Croscarmelosa Na
32,00 4,71 5,00 0,74
Aerosil
5,00 0,74 5,00 0,74
Kollidon VA 64
0,00 0,00 28,00 4,12
Estearato de Mg (E572)
10,00 1,47 10,00 1,47
678,80
100,00 678,80 100,00
Película
Ejemplo 4a Ejemplo 5a
Hipromelosa
10,80 10,80
Dióxido de titanio
3,24 3,24
Polietilenglicol
3,60 3,60
Oxido de hierro, rojo
0,36 0,36
18,00
18,00
Comprimido recubierto con película (CP)
696,80 696,80
Procedimiento de fabricación
Granulación en seco Granulación en seco
Tabla 3
Núcleo
Ejemplo 6 (comparativo) % en peso
Moxifloxacino-HCI
436,80 64,35
CMC (E460 (1))
136,00 20,04
Monohidrato de lactosa
68,00 10,02
Manitol
0,00 0,00
Croscarmelosa Na
32,00 4,71
Estearato de Mg (E572)
6,00 0,88
Aerosil
0,00 0,00
678,80
100,00
Película
No hay fabricación de comprimidos recubiertos con película
Procedimiento de fabricación
Granulación acuosa
Tabla 4
Ejemplo 6 comparativo
Ejemplo 1 Ejemplo 2 Ejemplo 3 Ejemplo 4 Ejemplo 5
Fuerza de compresión [kN] FCPrev FCPrin DT [%]
14 23 4,3 12 23 5,5 12 23 4,2-6,8 12 23 8,6 8 15 7,22 8 15 4,78
RR núcleos [N]/DT [%]
152,66 / 7,42 250,72 / 7,17 230,43 / 5,94 235,6 / 5,36 188 / 7,32 200 / 5,63
Abrasión núcleos [%]
Con cubierta; >1 % 0,26 0,25 0,31 0,55 0,41
Desprendimiento [%]
1 0 0 0 0 0
RR CP [NJ/DT [%]
No se puede barnizar 313,13/6,13 285,6/6,77 290,03/8,95 271,73 284
Disgregación CP [min]
No se ha fabricado ningún CR 1 '43" 2'29" 2'25" 1'25" 4'07"
RR = Resistencia a la rotura FCPrev = Fuerza de compresión previa FCPrin = Fuerza de compresión principal DT = Desviación típica

Claims (1)

  1. imagen1
ES09765042.8T 2008-12-08 2009-12-04 Moxifloxacino compactado Active ES2467105T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008061083 2008-12-08
DE102008061083 2008-12-08
PCT/EP2009/008692 WO2010066385A1 (de) 2008-12-08 2009-12-04 Kompaktiertes moxifloxacin

Publications (2)

Publication Number Publication Date
ES2467105T3 ES2467105T3 (es) 2014-06-11
ES2467105T5 true ES2467105T5 (es) 2017-12-05

Family

ID=41600617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09765042.8T Active ES2467105T5 (es) 2008-12-08 2009-12-04 Moxifloxacino compactado

Country Status (6)

Country Link
US (2) US20110293717A1 (es)
EP (3) EP2735307A1 (es)
EA (1) EA028676B1 (es)
ES (1) ES2467105T5 (es)
PL (1) PL2364141T5 (es)
WO (1) WO2010066385A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102204911B (zh) * 2011-03-25 2013-04-17 华润赛科药业有限责任公司 一种盐酸莫西沙星药物组合物及其制备方法
KR101435244B1 (ko) * 2011-04-12 2014-08-29 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
CN103284962B (zh) * 2012-02-23 2015-09-16 重庆圣华曦药业股份有限公司 莫西沙星分散片及制备方法
CN103301080B (zh) * 2012-03-15 2014-12-10 成都国为医药科技有限公司 一种含有盐酸莫西沙星的药物组合物及其制备方法
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
GR1008169B (el) * 2013-03-19 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
CN104622821B (zh) * 2013-11-13 2018-04-10 武汉先路医药科技有限公司 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления
SG11201610921PA (en) * 2014-07-18 2017-02-27 Msd Wellcome Trust Hilleman Lab Pvt Ltd A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
CN106074413A (zh) * 2016-07-20 2016-11-09 南通雅本化学有限公司 一种含有莫西沙星的药物组合物
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE4200414A1 (de) 1992-01-10 1993-07-15 Bayer Ag Chinolon- und naphthyridon-carbonsaeure-derivate
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PL192273B1 (pl) 1997-09-25 2006-09-29 Bayer Ag Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
HU229065B1 (en) 1998-11-10 2013-07-29 Bayer Ip Gmbh Pharmaceutical moxifloxacin compositions
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7230006B2 (en) * 2003-04-09 2007-06-12 Reddy's Laboratories Limited Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
WO2005020998A1 (en) 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US8377994B2 (en) * 2006-05-10 2013-02-19 Evonik Degussa GmeH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
EP2076249A2 (en) * 2006-10-27 2009-07-08 FMC Corporation Dry granulation binders, products, and use thereof
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
FR2992218B1 (fr) * 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation

Also Published As

Publication number Publication date
EP2364141A1 (de) 2011-09-14
EP2364141B1 (de) 2014-03-05
PL2364141T5 (pl) 2018-02-28
EA028676B1 (ru) 2017-12-29
EP2837376A2 (de) 2015-02-18
EP2837376A3 (de) 2015-03-25
PL2364141T3 (pl) 2014-07-31
WO2010066385A1 (de) 2010-06-17
US20150133489A1 (en) 2015-05-14
EA201170777A1 (ru) 2011-12-30
ES2467105T3 (es) 2014-06-11
EP2735307A1 (de) 2014-05-28
EP2364141B2 (de) 2017-08-02
US20110293717A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
ES2467105T5 (es) Moxifloxacino compactado
ES2754573T3 (es) Formulación de comprimido recubierto y método
US12064434B2 (en) Ribociclib tablet
BRPI0714915A2 (pt) composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
CA2619477A1 (en) Pancreatin micropellet cores suitable for enteric coating
CA2797812C (en) Enteric tablet
BR112016001822B1 (pt) Comprimido farmacêutico compreendendo ácido acetilsalicílico e clopidogrel e seu processo de fabricação
ES2435943T3 (es) Formulaciones de vildagliptina
CN111212641A (zh) 阿普斯特的药物组合物
ES2659369T3 (es) Composición de ropinirol
US8920840B2 (en) Enteric tablet
CA3039820A1 (en) Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof
EP2600847A1 (en) Oral pharmaceutical formulations of esomeprazole in the form of mups (multi unit pellets system) tablets
EP3236952B1 (en) Pharmaceutical tablet composition
CN104644583A (zh) 一种含达比加群酯的多单元微丸片剂及其制备
EP2895171B1 (en) A stable pharmaceutical formulation containing vardenafil hydrochloride
CN106943405B (zh) 一种阿立哌唑制剂及其制备方法
US10919898B2 (en) Medical use of compound III
CN105636581A (zh) 药物组合物
CN103768034A (zh) 一种含有盐酸安非他酮的缓控释固体组合物
ES2683361T3 (es) Composiciones de Imatinib
JP2017137255A (ja) 着色素錠のアムロジピン含有配合錠
RU2453315C2 (ru) Фармацевтическая композиция для лечения аллергических заболеваний